|
|
 |
|
Viewing report
|
|
|
|
Biosimilars
Arena-International, March 2010
In an environment where resources are scarce and patents are fast expiring, effective product planning is paramount to ensuring the success of your organisation. Biologic drugs - noted as some of the most-expensive medicines - are major targets for cost savings. The developments facilitating follow-on biologics are gaining momentum, with significant commercial opportunities emerging.
This products combines the proceedings from VIB Pharma's 2010 Biosimilars conference in one resource.
VIBpharma delivered cutting edge conference content for professionals in pharmaceutical and biotech manufacturers dealing with the development of biosimilars. Now you can secure the latest information in this space without venturing outside your office.
This package includes audio and presentation materials from the keynote speeches, industry-leading case studies and insightful Q&A sessions; ensuring you and your colleagues remain at the forefront of this rapidly developing industry.
Scope:
- A holistic look at the opportunities in the biosimilars market, from traditional pharma and generics leaders
- Learn about the potential of monoclonal antibodies (Mabs) in the current situation of expiring patents
- A practical examination of the impact of biosimilars
- Explore the potential of biobetters
- Legal and regulatory positions in addition as business considerations presented by an expert speaker faculty
Reaons to buy:
- Identify current and future trends to maximise the profitability of your biosimilars sector
- Achieve a critical analysis of the current market trends and developments to understand the impact of biosimilars on your competitors
- Outline the biosimilars status in emerging markets and how you can learn and benefit from their expansion
- Evaluate the global biosimilars market to assess its potential and profitability to your business
- Assess the global legislative environment for biosimilars to understand the current market developments
- Understand the mechanisms to review pricing strategy in order to secure preferential reimbursement status
|
|
|
|
